Related Experiment Video
Updated: Jan 27, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression
Yichong Ning1,2, Chunqing Wang1,2,3, Xin Liu1,2,4
1State Key Laboratory of Developmental Biology of Freshwater Fish, College of Life Science, Hunan Normal University, Changsha, 410081, Hunan, China.
Background:
Dysfunction of p53 is a key cause of cancer development, while CCDC106 can reduce p53 stability and is associated with lung cancer. However, the roles of CCDC106 in other cancer types and its upstream regulators have not been investigated.
Methods:
The phosphorylation status was investigated by in vitro kinase assay and Western blotting using phosphorylation-specific antibodies. Co-immunoprecipitation assay and GST-pulldown were used to detect protein interaction. Cell viability, apoptosis, colony formation, wound-healing and invasion assays were measured for in vitro functional analyses. The in vivo effect of CCDC106 on tumor growth was investigated using a subcutaneous xenograft tumor mouse model.
Results:
We demonstrated that CCDC106 knockdown enhanced apoptosis by stabilizing p53 and suppressed cell viability, colony formation, migration and invasion in cervical cancer HeLa and breast cancer MCF7 cells with wild-type p53 (wtp53), whereas CCDC106 overexpression exerted the opposite effects in normal breast epithelial HBL100 and cervical cancer SiHa cells with wtp53. However, CCDC106 had no similar effects on p53-mutant cervical and breast cancer cells (C33A and MDA-MB-231). Further study showed that CK2 interacts with CCDC106 through its regulatory β subunit and then phosphorylates CCDC106 at Ser-130 and Ser-147. The phosphorylation of CCDC106 at Ser-130 and Ser-147 is required for its interaction with p53 and nuclear localization, respectively. Inhibiting CCDC106 phosphorylation by substituting both Ser-130 and Ser-147 with alanine or treating cells with the CK2 inhibitor CX-4945 abrogated CCDC106-induced p53 degradation and its oncogenic function in cells with wtp53. Wildtype CCDC106, but not Ser-130/- 147 mutant CCDC106, enhanced tumor growth and p53 degradation in a xenograft mouse model. Moreover, suppression of CCDC106 increased CX-4945 sensitivity of cancer cells with wtp53.
Conclusion:
This study revealed a CK2/CCDC106/p53 signaling axis in the progression of breast and cervical cancers, which may provide a new therapeutic target for cancer treatment.
Insights
Dysfunctional p53 protein is linked to cancer. This study identifies a CK2/CCDC106/p53 signaling pathway promoting breast and cervical cancer progression, offering a potential new therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- p53 protein dysfunction is a critical driver of cancer development.
- CCDC106 protein has been implicated in reducing p53 stability and is associated with lung cancer.
- The specific roles of CCDC106 in other cancer types and its upstream regulatory mechanisms remain largely unexplored.
Purpose of the Study:
- To investigate the role of CCDC106 in breast and cervical cancers.
- To identify upstream regulators of CCDC106.
- To elucidate the molecular mechanisms by which CCDC106 influences cancer progression and p53 stability.
Main Methods:
- In vitro kinase assays and Western blotting were used to analyze protein phosphorylation.
- Co-immunoprecipitation and GST-pulldown assays were employed to determine protein interactions.
- Functional assays included cell viability, apoptosis, colony formation, migration, and invasion assays. In vivo studies utilized a xenograft mouse model.
Main Results:
- CCDC106 knockdown stabilized p53, enhancing apoptosis and suppressing proliferation, migration, and invasion in cervical and breast cancer cells with wild-type p53 (wtp53).
- Overexpression of CCDC106 had opposing effects. CCDC106 did not affect p53-mutant cancer cells.
- CK2 phosphorylates CCDC106 at Ser-130 and Ser-147, which is crucial for its interaction with p53 and nuclear localization, respectively. Inhibition of this phosphorylation abrogated CCDC106's oncogenic functions.
- Wild-type CCDC106 promoted tumor growth and p53 degradation in vivo. Suppression of CCDC106 increased sensitivity to the CK2 inhibitor CX-4945.
Conclusions:
- A novel CK2/CCDC106/p53 signaling axis was identified, playing a significant role in the progression of breast and cervical cancers.
- This signaling pathway represents a potential therapeutic target for treating these cancers.
- Targeting CCDC106 or its upstream regulators may enhance the efficacy of existing cancer therapies.
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Energy-requiring Steps of Glycolysis
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Proteins: From Genes to Degradation
Transcription is the synthesis of RNA...

